{"id":3577,"date":"2026-10-02T09:00:00","date_gmt":"2026-10-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3577"},"modified":"2026-10-02T19:41:50","modified_gmt":"2026-10-02T23:41:50","slug":"epitranscriptomic-tuning-broadens-in-vivo-car-design","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3577","title":{"rendered":"Epitranscriptomic Tuning Broadens In-Vivo CAR Design"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Osaka University<\/p>\n

Event Type<\/strong><\/p>\n

Publication \/ Peer-Reviewed Study<\/p>\n

Modality<\/strong><\/p>\n

mRNA-LNP In-Vivo CAR Platform (m6A-Modified)<\/p>\n

Asset<\/strong><\/p>\n

Modular In-Vivo CAR mRNA System (Preclinical)<\/p>\n

Target<\/strong><\/p>\n

FAP \/ EpCAM \/ LGR5 \/ CD133 (Interchangeable)<\/p>\n

Disease Area<\/strong><\/p>\n

Solid Tumors (Preclinical Models)<\/p>\n

Summary<\/h4>\n

Osaka University researchers report a modular mRNA\u2013lipid-nanoparticle system that generates transient CAR activity in vivo and uses mRNA methylation state to tune immune programs. Target substitution across FAP, EpCAM, LGR5 and CD133 supports platform flexibility, but the evidence is preclinical and does not yet solve cell-selective delivery or human safety.<\/p>\n

The peer-reviewed Scientific Reports paper was published online 2 October 2026. The system combined pH-responsive polybetaine lipid nanoparticles with N6-methyladenosine-modified CAR mRNA. In reported cell and mouse studies, FAP-directed constructs altered immune and memory-associated programs and suppressed tumor-associated SPP1 pathways. Replacing FAP specificity with EpCAM, LGR5 or CD133 preserved antitumor responses in the tested models. No human dosing, clinical manufacturing release criteria, biodistribution dataset or long-term genotoxicity outcome was reported.<\/p>\n

Deep Analysis<\/h4>\n

Transient mRNA avoids genomic integration and may allow exposure to decay if toxicity emerges. Epitranscriptomic modification can change translation, innate sensing and persistence, offering a programmable layer beyond receptor sequence. The central unresolved issue is who receives the nanoparticle: broad systemic transfection could create CAR expression in unintended cells or organs. Solid-tumor antigens such as FAP, EpCAM, LGR5 and CD133 also appear in normal or stem-cell compartments, raising on-target\/off-tumor risk. Mouse tumor control may not predict human trafficking, immunosuppression or cytokine burden. Scale-up must control lipid composition, RNA integrity, methylation, potency and lot-to-lot biodistribution.<\/p>\n

Interpretation A: mRNA chemistry and modular receptor exchange can create an adaptable in-vivo CAR platform. Cross-target activity and pathway changes support this; absent cell-selective delivery limits the claim. Interpretation B: antitumor effects reflect model-specific transfection and antigen abundance that will not yield a human therapeutic window. Broad target expression and incomplete biodistribution support caution, while transient exposure offers a safety lever. Human-relevant biodistribution, lineage-specific transfection, repeat-dose immunogenicity and large-animal tumor models would discriminate.<\/p>\n

Company and Product Background<\/h4>\n

Conventional CAR-T therapy requires ex-vivo cell collection, engineering and manufacturing. In-vivo CAR approaches deliver genetic instructions directly to the body, potentially simplifying logistics. mRNA produces transient receptor expression, while lipid nanoparticles protect and transport the RNA. FAP marks tumor stroma; EpCAM, LGR5 and CD133 are epithelial or stem-associated targets with variable normal-tissue expression.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Peer-reviewed preclinical platform paper published online 2 October 2026.<\/li>\n
  • m6A-modified CAR mRNA delivered by pH-responsive polybetaine nanoparticles.<\/li>\n
  • FAP, EpCAM, LGR5 and CD133 retargeting demonstrated modularity in tested models.<\/li>\n
  • Critical gap: selective immune-cell delivery and human therapeutic window.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The paper advances in-vivo CAR engineering by treating RNA chemistry as a controllable design variable. It is not evidence of clinical readiness. The platform becomes strategically important only if delivery can be restricted, exposure can be measured and solid-tumor antigen safety can be demonstrated.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: high for reported preclinical experiments; moderate for platform generalizability. Confidence in Interpretation: low-moderate. Red-team conclusion: modular retargeting in models does not establish comparable PK, biodistribution or safety across antigens.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Osaka University researchers report a modular mRNA\u2013lipid-nanoparticle system that generates transient CAR activity in vivo and uses mRNA methylation state to tune immune programs. Target substitution across FAP, EpCAM, LGR5 and CD133 supports platform…<\/p>\n","protected":false},"author":1,"featured_media":3589,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[906,905],"class_list":["post-3577","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-in-vivo-car","tag-osaka-university"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3577"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3577\/revisions"}],"predecessor-version":[{"id":3596,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3577\/revisions\/3596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3589"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}